Ikarian Capital, LLC Esperion Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.73 - $3.08 $1.02 Million - $4.31 Million	-1,400,000 Reduced 80.57%	337,636 $1.01 Million
Q3 2023 Nov 14, 2023	BUY	$0.96 - $1.79 $30,749 - $57,335	32,031 Added 1.88%	1,737,636 $1.7 Million
Q2 2023 Aug 14, 2023	BUY	$1.2 - $1.76 $420,000 - $616,000	350,000 Added 25.82%	1,705,605 $2.37 Million
Q1 2023 May 15, 2023	SELL	$1.46 - $7.3 $781,891 - $3.91 Million	-535,542 Reduced 28.32%	1,355,605 $2.16 Million
Q4 2022 Feb 14, 2023	SELL	$5.09 - $8.5 $1.22 Million - $2.04 Million	-240,000 Reduced 11.26%	1,891,147 $11.8 Million
Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $417,170 - $622,310	76,545 Added 3.73%	2,131,147 $14.3 Million
Q2 2022 Aug 12, 2022	BUY	$4.77 - $6.67 $9.8 Million - $13.7 Million	2,054,602 New	2,054,602 $13.1 Million

206

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $153M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.